Your browser doesn't support javascript.
loading
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Wang, Zebin; Grosskurth, Shaun E; Cheung, Tony; Petteruti, Philip; Zhang, Jingwen; Wang, Xin; Wang, Wenxian; Gharahdaghi, Farzin; Wu, Jiaquan; Su, Nancy; Howard, Ryan T; Mayo, Michele; Widzowski, Dan; Scott, David A; Johannes, Jeffrey W; Lamb, Michelle L; Lawson, Deborah; Dry, Jonathan R; Lyne, Paul D; Tate, Edward W; Zinda, Michael; Mikule, Keith; Fawell, Stephen E; Reimer, Corinne; Chen, Huawei.
Afiliación
  • Wang Z; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Grosskurth SE; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Cheung T; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Petteruti P; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Zhang J; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Wang X; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Wang W; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Gharahdaghi F; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Wu J; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Su N; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Howard RT; Institute of Chemical Biology, Department of Chemistry, Imperial College London, London, United Kingdom.
  • Mayo M; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Widzowski D; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Scott DA; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Johannes JW; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Lamb ML; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Lawson D; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Dry JR; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Lyne PD; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Tate EW; Institute of Chemical Biology, Department of Chemistry, Imperial College London, London, United Kingdom.
  • Zinda M; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Mikule K; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Fawell SE; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Reimer C; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Chen H; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston, Waltham, Massachusetts. Raymond.chen@astrazeneca.com.
Cancer Res ; 78(23): 6691-6702, 2018 12 01.
Article en En | MEDLINE | ID: mdl-30297535
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ADP Ribosa Transferasas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Huso Acromático Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ADP Ribosa Transferasas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Huso Acromático Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article